

An Aerosolized Connexin43 Mimetic Peptide (aCT1) Improves Clinical Metrics in Animal Models of Acute Lung Injury

Meghan A. Bowler, PhD, Carissa C. James, PhD, Lauren A. Jeffers, PhD, Yasmin K. Ibrahim, PhD, Michael Koval, PhD, and Christina L. Grek, PhD

July 18th, 2022 – Morning Plenary Session of IGJC

Disclosures

Employment

• Dr. Meghan Bowler is currently a full-time employee of Xequel Bio

Intellectual Property

 Xequel Bio holds >50 granted US and international patents that protect aCT1 technology's use

Funding

- Work was partially funded by the National Institutes of Health
- Work was partially funded by the Department of Defense
- Work was partially funded by Xequel Bio



Overview

Company Snapshot Introduction to aCT1 Technology Efficacy in Acute Lung Injury Models Translational Relevance and Feasibility

Company Snapshot

Etiology Agnostic Therapeutic

- Platform technology in Dermatology, Ophthalmology, and Pulmonology
- aCT1 peptide (New Chemical Entity) has been rigorously tested for safety and efficacy in preclinical and clinical studies
- Developed as a molecular tool to probe gap junctions





Jerry St. Peter, CEO

Wes Brazell, CFO

David Leffell, MD, CMA



Christina Grek, PhD Sr. Director of R&D




Carissa James, PhD

Director of R&D




Meghan Bowler, PhD Translational Scientist


aCT1 peptide




Rhett et al. 2008 Trends Biotech Rhett et al. 2011 MBoC Palatinus et al. 2011 AJP Heart Circ Phys Montgomery et al. 2021 FASEB Jiang et al. 2019 JAHA




aCT1 peptide




Rhett et al. 2008 Trends Biotech Rhett et al. 2011 MBoC Palatinus et al. 2011 AJP Heart Circ Phys Montgomery et al. 2021 FASEB Jiang et al. 2019 JAHA



aCT1 peptide




Rhett et al. 2008 Trends Biotech Rhett et al. 2011 MBoC Palatinus et al. 2011 AJP Heart Circ Phys Montgomery et al. 2021 FASEB Jiang et al. 2019 JAHA







aCT1 peptide




Rhett et al. 2008 Trends Biotech Rhett et al. 2011 MBoC Palatinus et al. 2011 AJP Heart Circ Phys Montgomery et al. 2021 FASEB Jiang et al. 2019 JAHA








CONFIDENTIAL



CONFIDENTIAL


aCT1 to Treat SARS-CoV-2 Induced Lung Injury



Yuan et al. 2020 Nat Microbiol

Created with Biorender.com


aCT1 Reduces Inflammation and Edema in Acute Lung Injuries



Representative 4X images of lung tissue 7 days after SARS-CoV-2 infection




aCT1 Reduces Inflammation and Edema in Acute Lung Injuries



Representative 4X images of lung tissue 7 days after SARS-CoV-2 infection




- Infected
- Infected + Remdesivir
- Infected + Remdesivir + aCT1




aCT1 Reduces Inflammation and Edema in Acute Lung Injuries

Aerosolized aCT1 prevents COVID-19 induced pulmonary edema and reduces infiltration of inflammatory cells.




Representative 4X images of lung tissue 7 days after SARS-CoV-2 infection





aCT1 to Treat Alcoholic Lung Syndrome



Smith et al. 2019 Alcohol




1. Inject Evans Blue dye



Smith et al. 2021 Methods Mol Biol




1. Inject Evans Blue dye 2. Allow dye to circulate




Smith et al. 2021 Methods Mol Biol






Smith et al. 2021 Methods Mol Biol






Smith et al. 2021 Methods Mol Biol







Smith et al. 2021 Methods Mol Biol









24

24

0


0

Created with Biorender.com


Time (hrs):

Aerosolized aCT1 to Treat Acute Lung Injury


Aerosolized aCT1 prevents COVID-19 induced pulmonary edema and reduces infiltration of inflammatory cells.




Aerosolized aCT1 improves pulmonary barrier function in models of alcoholic lung syndrome after acute lung injury.



Aerosolized aCT1 Delivery



Created with Biorender.com



Created with Biorender.com



Aerosolized aCT1 peptide:

- Has demonstrated efficacy in translationally relevant models of several acute lung injuries
 - SARS-CoV-2 induced lung injury
 - Alcoholic lung syndrome + acute lung injury
 - Human lung cells
- Reaches distal airspaces
- Has an attractive particle distribution profile
- Has demonstrated no adverse effect on pulmonary function

Aerosolized aCT1 peptide is an etiology agnostic respiratory therapeutic that holds immense potential for treatment of acute lung injury and many other conditions with unmet clinical needs.



Acknowledgements

Koval Lab

EMORY



• Yasmin K. Ibrahim

Michael Koval, PhD

Lovelace Biomedical Research Institute

115

- Melanie Doyle-Eisele, PhD
- Hammad Irshad, MS
- David Revelli, PhD



Division of Pulmonary, Critical Care & Sleep

ARTMENT of MEDICINE in the COLLEGE of MED

Atkinson Lab

Carl Atkinson, PhD

Xequel Bio

- Christina L. Grek, PhD
- Carissa C. James, PhD

Funding

NIH

- Department of Defense

 Enhancement Award
- National Institutes of Health

 Phase I SBIR Award


National Institutes


of Health




Visit Us at Our Booth!

mbowler@xequel.com cjames@xequel.com





Created with Biorender.com



xequelbio

Aerosolized aCT1 Delivery

